In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...

A St. Johns County man has been charged with illegally selling weight-loss drug ingredients. Adam K. Taylor is accused of ...

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

New research challenges fears about Ozempic weight regain. Cleveland Clinic study of 8,000 patients finds minimal rebound after stopping GLP-1 medications.

CagriSema is has been positioned as a next-level GLP-1. Even if it doesn't dethrone the greats, doctors say it could still ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...

Research out today might provide even more of a reason for people to stay on GLP-1 medications like semaglutide, the active ...

Drugs such as Ozempic and Wegovy may be able to help alleviate symptoms of anxiety and depression, a new study suggests.

Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.

Ozempic has been a breakthrough for many, correcting eating disorders and managing blood sugar, weight, and more. A recent New Yorker article highlights an under-discussed bio-psychological side ...